Inhibrx Inc stock (US45720L1070): trial update around ozekibart keeps biotech investors watching

Inhibrx Inc has drawn fresh attention after its partner Transcenta reported updated Phase 1/2 data for ozekibart (INBRX-109) in colorectal cancer, while the company also submitted a US Biologics License Application for the same antibody in chondrosarcoma.

Inhibrx Inc is back in focus after partner Transcenta Holding announced that Inhibrx recently reported positive updated interim data from its Phase 1/2 study of ozekibart (INBRX-109) in combination with FOLFIRI in patients with advanced colorectal cancer, alongside news that a Biologics License Application for ozekibart in conventional chondrosarcoma was filed with the US Food and Drug Administration in April 2026, according to HKEXnews as of 05/21/2026 and AAStocks as of 05/21/2026.

As of: 05/21/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Inhibrx Biosciences, Inc.
• Sector/industry: Biotechnology / biopharmaceuticals
• Headquarters/country: San Diego, United States
• Core markets: US and global oncology and rare disease markets
• Key revenue drivers: Pipeline progress, licensing deals, potential future product sales
• Home exchange/listing venue: Nasdaq (ticker: INBX)
• Trading currency: USD

Inhibrx Inc: core business model

Inhibrx Inc is a clinical-stage biopharmaceutical company focused on developing biologic therapeutics, particularly engineered antibodies, for oncology and rare diseases. The group aims to design molecules that precisely target disease pathways while maintaining favorable safety profiles. As a clinical-stage business, Inhibrx does not yet rely on large-scale commercial product sales but instead depends on external funding, collaboration payments and potentially milestone income. This model is typical for US biotech companies seeking to advance high-risk, high-reward assets through the clinic.

The company’s strategy centers on a pipeline of differentiated biologics, of which ozekibart (also referred to as INBRX-109) is currently one of the most advanced and visible candidates. Ozekibart is being developed as an agonist antibody targeting death receptor 5 (DR5), intended to trigger cancer cell death while aiming to avoid the toxicity issues seen in some earlier DR5-targeting projects. By using proprietary engineering platforms, Inhibrx seeks to fine-tune properties such as potency, half-life and tissue specificity, with the goal of creating novel therapeutic options in indications where existing treatments leave significant unmet need.

From an operational standpoint, Inhibrx follows the broadly established biotech model of taking molecules through early and mid-stage trials and, depending on resources, either partnering with larger pharmaceutical groups or retaining more commercial rights. This approach allows the company to leverage external expertise, especially outside the United States, while preserving value in key territories. The collaboration with Transcenta, which highlighted the colorectal cancer data in a stock exchange filing in Hong Kong, is an example of how Inhibrx can extend the reach of its programs beyond its home market.

Main revenue and product drivers for Inhibrx Inc

The most closely watched near-term driver for Inhibrx is the regulatory and commercial trajectory of ozekibart in conventional chondrosarcoma, a rare bone cancer with no currently approved systemic therapies. According to Transcenta’s announcement summarizing Inhibrx disclosures, the company submitted a Biologics License Application to the FDA for this indication in April 2026, representing a key milestone for the program and for the company’s potential transition toward a commercial-stage profile, as reported by HKEXnews as of 05/21/2026.

In addition to the regulatory progress in chondrosarcoma, investors are tracking the performance of ozekibart in other tumor types. The updated interim results in colorectal cancer, reported by Transcenta based on Inhibrx data, showed that in a cohort of 45 evaluable patients with locally advanced or metastatic, unresectable colorectal cancer treated with ozekibart plus FOLFIRI, the objective response rate reached 20 percent per RECIST v1.1, while the disease control rate was reported at 87 percent. Median progression-free survival in the evaluable population was 5.5 months, and nine patients remained on therapy at the time of the data cut, suggesting a subset with durable disease control, according to AAStocks as of 05/21/2026.

These mid-stage data also included safety observations, which are critical for the long-term commercial viability of any oncology antibody. Transcenta reported that the most common treatment-related adverse events in the study were diarrhea, fatigue and nausea, largely of Grade 1 or 2 severity and consistent with the known side-effect profile of FOLFIRI chemotherapy. Notably, despite around 68 percent of patients presenting with liver metastases at baseline, no significant liver toxicity was observed, according to the same AAStocks summary. For a DR5 agonist antibody, a manageable hepatic safety profile is particularly important, since earlier molecules in this class in the industry had raised concerns about liver-related adverse events.

Beyond ozekibart, Inhibrx’s broader pipeline includes additional antibody and biologic programs, though publicly available summaries tend to focus on the lead asset. For a clinical-stage biotech, each program is a potential source of future licensing income or, if successful in late-stage trials, sales revenues. However, until any of these candidates achieve regulatory approval and market uptake, Inhibrx is expected to remain reliant on financing transactions such as equity offerings and possibly strategic partnerships to fund ongoing research and development. This dependence on external capital is typical for the sector and can lead to share price volatility when market sentiment toward high-growth, loss-making biotechnology companies shifts.

According to stock market data cited by a major US trading platform, Inhibrx shares recently traded around the low triple-digit dollar range, with a market capitalization in the mid single-digit billion-dollar area and a negative price-to-earnings ratio reflecting ongoing losses typical of a development-stage biotech, as indicated by Robinhood as of 05/21/2026. The absence of positive earnings underscores that fundamental valuation is driven less by current profitability and more by expectations surrounding the clinical pipeline, regulatory news and potential partnering or acquisition scenarios in the biotech ecosystem.

Why Inhibrx Inc matters for US investors

For US investors, Inhibrx represents one of several Nasdaq-listed biotechnology companies attempting to translate advanced antibody engineering platforms into commercially viable therapies. Its programs target oncology and rare diseases, areas that have historically attracted substantial investor interest due to the potential for premium pricing and, in some cases, orphan-drug incentives in the US market. The chondrosarcoma BLA filing, if accepted and later approved, could position the company within a niche yet high-need segment of the oncology landscape, potentially making Inhibrx a more visible player among specialized US healthcare portfolios.

The US listing also offers domestic investors easier access to liquidity and trading compared with some foreign biotech names. In addition, regulatory events involving the FDA – such as acceptance of the ozekibart filing, advisory committee meetings and eventual approval or rejection decisions – tend to occur during US market hours and can have an immediate impact on the share price. For investors following the broader US biotech sector, Inhibrx can be viewed as part of the cohort of companies where binary clinical and regulatory milestones may dominate short-term market performance, while longer-term value is tied to building a diversified pipeline and, eventually, recurring product revenues.

Conclusion

Inhibrx Inc is drawing renewed attention after updated ozekibart data in colorectal cancer and the submission of a Biologics License Application for conventional chondrosarcoma put its lead antibody at the center of the investment case. The interim study results reported by Transcenta highlight a combination of response rate, disease control and manageable safety that may justify continued exploration of the regimen in heavily pretreated patients, while the lack of approved systemic therapies in chondrosarcoma underscores the medical need the company is targeting. At the same time, Inhibrx remains a clinical-stage biotech with negative earnings and dependence on external funding, meaning that the stock is likely to stay sensitive to clinical, regulatory and capital-market developments. For US investors following the biotechnology sector, the coming regulatory milestones for ozekibart and the evolution of the pipeline as a whole will be central to assessing how the company’s risk profile evolves over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.